Objective: Depression occurs in 18% to 45% of patients with coronary artery disease (CAD) where it is associated with an increased risk of acute coronary events and mortality. Our objective was to quantitatively summarize the data on the efficacy and tolerability of antidepressant (AD) treatment for depression in CAD.
S tudies have typically defined CAD as ischemic symptoms leading to coronary angiographic evidence of a 50% or more blockage in at least one major coronary artery, previous hospitalization for an acute coronary syndrome such as MI, or previous revascularization such as PCI or CABG. 1 Such patients commonly present with mood symptoms ranging from minor depression to major depressive episodes. 2 While major depression has a lifetime prevalence of 4.4% to 20% in the general population, [3] [4] [5] [6] the prevalence in CAD patients is at least 2-fold higher; about 20% of patients with CAD suffer from major depression within 1 year following an acute coronary syndrome, while another 27% do not meet diagnostic criteria for major depression but report significant depressive symptoms or suffer from minor depression. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] Among all patients with CAD, both major and minor depression are significantly and substantially associated with an increased risk of mortality or MI independently of traditional cardiac risk factors. 8, 10, 11, [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] Despite this association, depression and depressive symptoms frequently remain untreated in CAD. 29, 30 Given that CAD is the leading cause of morbidity and mortality in North America, 31, 32 the impact of depression in this population is substantial.
It has been suggested that a lack of knowledge concerning the clinical evidence around the tolerability and efficacy of ADs in this population may be a contributor to undertreatment. 33 There have been a limited number of randomized, double-blind, placebo-controlled trials investigating the efficacy and tolerability of ADs in CAD. 34 In these individual trials, SSRIs and a NaSSA appear to exhibit efficacy and tolerability in some [35] [36] [37] but not all trials. 38, 39 Meta-analytical techniques can be employed to quantitatively incorporate outcomes of different trials to strengthen the evidence from individual studies. We conducted a meta-analysis of AD trials in CAD to quantify the therapeutic effect of these medications, estimate tolerability, and calculate the NNT for response and side-effects.
Methods
The study population was defined to include adults diagnosed with CAD, including patients with histories of MI, CABG, PCI, or the presence of ischemic heart disease. Studies were included whose subjects met the DSM-IV 40 criteria for major depression or minor depression. Minor depression shares diagnostic criteria with major depression but stipulates the presence of fewer criterion symptoms. 40 Only original reports of double-blind, randomized, placebo-controlled clinical trials were included.
This analysis was performed according to the Quality of Reporting of Meta-Analyses guidelines. 41 We searched English-language literature using MEDLINE from June 1960 to March 2008 using the key words depression, heart disease, CAD, and AD. Additional searches also included each of the primary AD classes: SSRIs, tricyclic ADs, monoamine oxidase inhibitors, NaSSAs, and serotonin-norepinephrine reuptake inhibitors. The Cochrane Database, EMBASE, Allied and Complementary Medicine Database for British Library, Cinahl, AgeLine, and PsycINFO were also searched, as were the references of relevant review articles. References in all retrieved articles were also searched for additional relevant studies. To find unpublished studies, we searched through all the clinical trials that were registered in the National Institutes of Health Clinical Trial Registry, Australian and New Zealand clinical trial registry, the University Hospital Medical Information Network, the Netherlands Trial Register, and the International Standard Randomized Controlled Trial Number Registry.
The designs of the retrieved studies were examined by 2 independent raters, and a quality rating was calculated using the previously validated [42] [43] [44] Jadad Scale. 44 Disagreements regarding inclusion and quality were settled by consensus.
The results section of each relevant article was examined by 2 independent raters, and data for each of the following outcome categories were extracted: mean decrease in HDRS, 45 mean decrease in BDI, 46 number of patients responding to treatment, number achieving remission of depression, number reporting adverse events, treatment discontinuation (dropout) for any reason, and dropout owing to adverse events.
Response was defined as a 50% or greater reduction in the 21-item HDRS, a standardized measure for depression. Remission was defined as a score of 8 or less on the 21-item HDRS. Other definitions of remission or response were also considered if they were deemed clinically valid and (or) relevant. Adverse events were defined in this analysis as any treatment-emergent adverse event reported by the original study authors.
We used Review Manager Version 5.0 (Cochrane, Oxford, UK) for analysis. For dichotomous outcomes of interest, pooled odds ratios and 95% confidence intervals were calculated using a random effects model. For continuous data, a WMD and 95% confidence intervals were calculated, also using a random effects model. Heterogeneity was tested for all combined results by means of chi-square analysis, and I² was calculated to determine the impact of heterogeneity. 47 Publication bias was assessed where there were 5 or more studies using funnel plots and rank correlations. 48, 49 The NNT and NNH were calculated 50 when odds ratios were significant. The NNT is the reciprocal of the risk difference when the assessed outcome is desirable, and the NNH is the reciprocal of the risk difference when the assessed outcome is undesirable.
Results
We found no unpublished trials. Among the 26 potentially relevant publications of 18 distinct clinical trials, 2151 to 2171 were excluded for the following reasons: the article was not an original report of a clinical trial (n = 8), the trial was not randomized (n = 4), not double-blind (n = 4), not placebocontrolled (n = 9), and (or) there was no depression outcome (n = 15). Four different clinical trials met the inclusion criteria, [35] [36] [37] [38] [39] with data from Sertraline Antidepressant Heart Attack Randomized Trial extracted from 2 different publications 35, 36 ). All studies had a Jadad quality score of greater than 4. In one of the studies, they also had patients in groups such as interpersonal therapy and clinical management, which we only included in the group of patients who were randomized to just placebo and AD. 37 Publication bias was not identified among the studies as demonstrated by a funnel plot of mean decrease in HDRS scores for response and remission rates. These studies examined AD therapy (fluoxetine, sertraline citalopram, and mirtazapine) in 402 subjects and placebo treatment in 396 subjects (Table 1) . There was no significant heterogeneity in combined studies (P > 0.05) ( Table 2 ) except in one instance as described below.
AD Efficacy
The proportion of subjects who could be classified as responders could be extracted from 3 studies, 37-39 involving 429 subjects ( Figure 1A ). The overall odds ratios for response was 1.72 (95% CI 1.17 to 2.54). This indicates a statistically significant superiority of AD over placebo treatment ( Table 2 ). The corresponding NNT for response was 7 (95% CI 4 to 27).
The proportion of subjects who achieved remission could be extracted from 3 studies 37-39 involving 429 subjects ( Figure  1B ). The overall odds ratios for response was 1.80 (95% CI 1.18 to 2.74), which favoured the group treated with ADs ( Table 2 ). The corresponding NNT for remission was 8 (95% CI 4 to 32).
Change in depressive symptoms was measured by reduction in HDRS and BDI scores. Mean decrease in HDRS was reported in all 4 trials, 35, [37] [38] [39] involving 798 subjects ( Figure  2A ). The overall WMD for HDRS scores was 1.41 (95% CI 0.53 to 2.29). Mean decrease in BDI was reported in 3 studies, [36] [37] [38] involving 742 subjects ( Figure 2B ). The overall WMD for BDI scores was 2.27 (95% CI 0.60 to 3.94). Both WMDs favoured the group treated with ADs ( Table 2 ).
Tolerability
The proportion of subjects who dropped out for any reason was extractable from 4 studies 35,37-39 ( Figure 3A ). There was no statistically significant difference between the groups treated with placebo and AD (OR 0.84, 95% CI 0.42 to 1.68). However, significant heterogeneity was identified among the studies included in this analysis ( Table 2 ).
The proportion of subjects who dropped out owing to adverse events was extractable from 2 studies 35, 37 ( Figure 3B ). There was no statistically difference in dropout owing to adverse events between the AD group and placebo group (OR 1.30, 95% CI 0.75 to 2.25) ( Table 2) . 
Discussion
This meta-analysis suggests that patients (with CAD and who were depressed) treated with ADs demonstrate small but statistically significant reductions both in clinician-rated and in self-reported depressive symptoms (mean decreases in HDRS and BDI scores) as well as significantly improved rates of response and remission, compared with placebo. These data were summarized using NNT, which represent a clinically relevant format for reporting statistical information about an intervention. The NNT was 8 (4 to 32) for one additional CAD patient to achieve remission of depressive symptoms. For comparison, reported NNTs to achieve remission have been 4 for ADs for depression in medical illness, 72 between 1 to 8 for treatment of depression in cognitively intact elderly people, 73 and 3 to 5 for response in dysthymia in a younger adult population. 74 Thus the NNT reported here in patients with CAD is similar to that reported in other studies using ADs.
The most common adverse events among all the included studies were fatigue, headache, nausea, dizziness, diarrhea, and sweating. These are common side effects of ADs that have been reported with similar frequency in other populations including the elderly 75 and populations without cormorbid CAD. 76, 77 To quantify the tolerability of ADs in this population, we extracted the number of dropouts owing to adverse events. While this was not significantly different between patients receiving ADs and patients receiving placebo, readers should be cautioned that this was based on data from 2 studies. The tolerability data was summarized using the NNH, which was found to be 49. This is comparable to the NNH of 16 to 26 found in AD trials in other medical populations, [78] [79] [80] [81] suggesting that tolerability in patients with CAD is similar. We were unable to identify any effect, either positive or negative, on cardiac parameters in these studies based on the adverse events reported.
All-cause dropout data were extractable from all 4 trials included, showing no significant difference between intervention and placebo groups. Significant heterogeneity in all-cause dropout was detected between studies; however, necessitating that these data be interpreted with caution. We could not determine any a priori reason for heterogeneity in all-cause dropouts among the 4 included trials. Unmeasured intersite differences such as burden of trial or difference in frequency of visits in each trial may have led to unexpected differences in all-cause dropouts despite similarity on dropouts owing to adverse events.
While the population included in this meta-analysis was large enough to detect the effect of ADs in CAD, there are a small number of AD trials in patients with CAD. The included studies also differed by factors such as outcomes of interest, reporting of dropouts and adverse events, sample size, length of trial, length of time post acute coronary syndrome, whether overall results were significant and use of different ADs and dosages. Despite these differences, the impact of heterogeneity on primary outcome variable (mean decrease in HDRS) was small (I² = 0), suggesting that it was reasonable to combine them. Similarly, while 3 out of the 4 included clinical trials used an SSRI and only 1 study used a NaSSA, the lack of heterogeneity suggests that the efficacy of ADs was comparable in the trials included. Finally, the NaSSA trial was the only study identified that included patients with minor depression. Studies indicate that minor depression and subsyndromal depressive symptoms are also associated with a substantial disease burden in patients with CAD, 8, 16 and thus may be an important treatment target. The impact of severity of depressive symptoms could not be assessed with the current trials. Strengths of this meta-analysis are the lack of publication bias, use of random effects models, which makes no assumptions regarding homogeneity of study A recent meta-analysis performed in non-CAD populations has fuelled controversy regarding the efficacy of ADs. 82 That meta-analysis brought to light 2 main factors of relevance to the current meta-analysis. First, the so-called file drawer problem: many of the studies performed have not been published, and more so for negative studies. In that study, the unpublished studies were found by contacting the US Food and Drug Administration for the submission dossier of each AD. In this meta-analysis, as that is possible only for the pivotal RCTs in the initial approval package, we checked current databases listing RCTs and did not find any unpublished studies targeting those with CAD. This finding is corroborated by the lack of measureable publication bias in the studies collected and by the fact that both positive and negative studies were published. Nevertheless, small negative studies initiated prior to current RCT registration guidelines likely remain unpublished. The second issue of controversy is around the clinical significance of the mean difference between drug and placebo groups. The National Institute for Clinical Excellence guidelines for the management of depression in the United Kingdom specify a clinically significant effect size to be 0.5 or greater. 83 Indeed, the mean 
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Total events Heterogeneity: ² = 0.00; ² = 0.65, df = 2 (P = 0.72); I² = 0% Test for overall effect: Z = 2.77 (P = 0.006) difference demonstrated in both non-CAD meta-analyses is small, particularly in those with lower severities of depression. 84 Thombs et al, 85 reviewing the literature in patients with cardiovascular disease, found that the effect sizes for AD treatment ranged from 0.2 to 0.38 for the primary outcome variables. However, Thase and Kennedy 86 have demonstrated that hidden within those small mean differences is the fact that a greater proportion of patients on ADs, particularly those with more severe depression at baseline, do have a clinically significant response. In this meta-analysis, while the mean difference was also small, there were a greater proportion of patients who remitted in the AD treated groups with a 95% confidence interval ranging from 1.18 to 2.74. These findings suggest clinically meaningful changes.
Events
While this meta-analysis suggests a modest benefit with ADs, compared with placebo, in the treatment of depression in patients with CAD, there are other factors that must be considered. It is still unknown whether treatment with ADs will improve cardiac outcomes in those who respond to treatment, but screening and treatment will result in improving depression outcomes and quality of life in this group of patients. 85, 87 The negative effects of AD therapy, which include side effects, possible drug interactions, and discontinuation reaction, must also be considered. Therefore, treatment must be individualized based on patient characteristics.
Conclusion
This meta-analysis investigated the effect of ADs specifically in patients with CAD. Our results indicate that, in depressed patients with CAD, treatment with ADs, compared with placebo, results in a significant therapeutic benefit. A small number of patients need to be treated to achieve response and (or) remission of depressive symptoms. Importantly, this meta-analysis also suggests that ADs can be used in patients with depression and CAD safely and with good tolerability. Many clinically important questions remain to be studied, such as the relation between severity of depression and treatment response, the optimal time to begin pharmacotherapy, whether prophylaxis with ADs is beneficial compared with risks, and long-term effects of AD pharmacotherapy in this group. Nevertheless, these findings contribute to evidencebased knowledge and may help to ameliorate the present clinical bias that has been identified toward undertreatment. Conclusion : Le traitement de la dépression aux AD dans la coronaropathie produit des effets thérapeutiques significatifs sans taux d'abandon substantiellement accrus.
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